In mouse cancer models, in contrast to minimal effects of blockade of TIGIT or PD-L1 alone, combined blockade of TIGIT and PD-L1 can induce substantial tumor regression and improved survival by enhancing the function of CD8+ TILs (169). The gene discussed is CD274; the disease is neoplasm.